| Dr Sergio Adrian Vie, MD | |
|
1310 N 24th St Ste 150, Phoenix, AZ 85008-4617 | |
| (602) 254-0200 | |
| (602) 254-0237 |
| Full Name | Dr Sergio Adrian Vie |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 1310 N 24th St Ste 150, Phoenix, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235375486 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 17395 (Arizona) | Secondary |
| 208000000X | Pediatrics | 17395 (Arizona) | Primary |
| Entity Name | Navajo Health Foundation-sage Memorial Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477735777 PECOS PAC ID: 2163332347 Enrollment ID: O20040326001225 |
News Archive
Researchers at The University of Nottingham have been awarded £2.8 million by the Wellcome Trust to develop a new drug that could ease the suffering of hundreds of thousands of heart disease patients who are unable to take beta-blockers.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.
KAEL-GemVax, a leading oncology vaccine company, today announced, through its subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer. The company also strongly believes GV1001 has major "blockbuster" potential as a universal therapeutic cancer vaccine and is developing a strong pipeline for other indications, including lung and liver cancer and melanoma.
› Verified 9 days ago
| Entity Name | St Lukes Pediatrics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306078514 PECOS PAC ID: 0345551115 Enrollment ID: O20150619001334 |
News Archive
Researchers at The University of Nottingham have been awarded £2.8 million by the Wellcome Trust to develop a new drug that could ease the suffering of hundreds of thousands of heart disease patients who are unable to take beta-blockers.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.
KAEL-GemVax, a leading oncology vaccine company, today announced, through its subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer. The company also strongly believes GV1001 has major "blockbuster" potential as a universal therapeutic cancer vaccine and is developing a strong pipeline for other indications, including lung and liver cancer and melanoma.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sergio Adrian Vie, MD 10665 E Gold Dust Ave, Scottsdale, AZ 85258-6004 Ph: (602) 388-9335 | Dr Sergio Adrian Vie, MD 1310 N 24th St Ste 150, Phoenix, AZ 85008-4617 Ph: (602) 254-0200 |
News Archive
Researchers at The University of Nottingham have been awarded £2.8 million by the Wellcome Trust to develop a new drug that could ease the suffering of hundreds of thousands of heart disease patients who are unable to take beta-blockers.
Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.
A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.
KAEL-GemVax, a leading oncology vaccine company, today announced, through its subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer. The company also strongly believes GV1001 has major "blockbuster" potential as a universal therapeutic cancer vaccine and is developing a strong pipeline for other indications, including lung and liver cancer and melanoma.
› Verified 9 days ago
Dr. Amit Rajaram, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 1919 E Thomas Rd, Phoenix, AZ 85016 Phone: 602-933-0198 | |
Dr. Patricia Ranjinee Halpe, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3141 N 3rd Ave, Phoenix, AZ 85013 Phone: 602-914-1520 Fax: 602-914-1521 | |
Dr. Angela Monique Valdez-huizar, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 3333 E Van Buren St, Phoenix, AZ 85008 Phone: 602-933-0945 Fax: 602-933-4263 | |
Benjmamin Thomas Carlson, PTA Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 5314 N 7th St, Phoenix, AZ 85014 Phone: 602-277-5006 | |
Julianna Diddle, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1919 E Thomas Rd, Phoenix, AZ 85016 Phone: 602-933-1000 | |
Dr. Salil V. Pradhan, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2525 E Roosevelt St, Phoenix, AZ 85008 Phone: 602-344-5404 Fax: 602-344-5859 | |
Michael Clement, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 635 E Baseline Rd, Phoenix, AZ 85042 Phone: 602-243-7277 Fax: 602-243-1235 |